Decision on rights issue of units consisting of shares and warrants
The Board of PharmaLundensis AB (publ), corporate identity number 556708-8074, has decided on today 13 November 2019, supported by authorization from the Annual General Meeting of 11 June 2019, to carry out a rights issue of no more than 1,185,648 units. Each unit consists of 3 new shares and 2 free-of-charge warrants with the issue price of SEK 6 per unit, corresponding to a subscription price of SEK 2 per share. Each existing share gives entitlement to 1 unit right, and 20 unit rights give entitlement to subscribe for 1 unit. Subscription will take place with preference for existing shareholders. The subscription period is 29 November to 13 December 2019. Subscription for units without support of unit rights will take place in blocks of 250 units. At full subscription, PharmaLundensis will receive approximately SEK 7.1 million before issue costs, which are expected to be approximately SEK 250,000. Upon full exercise of the warrants, the company will in addition receive approximately SEK 4.7 million before issue costs.
Full text: ENG Press release 13 November 2019